HaiTao Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
HaiTao Zhao has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Yiyao Xu
Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
2 shared publications Cong Li
Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China
1 shared publicationDongKai Li
Chinese Academy of Medical Sciences and Peking Union Medical College
1 shared publicationGuangBing Li
Chinese Academy of Medical Sciences and Peking Union Medical College
1 shared publicationGuangbing Li
Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China
1 shared publicationHai-Feng Xu
1 shared publication
Latest Publications
- Open Access
- 31 October 2012
- Published by Springer Nature in Science China Life Sciences
- Vol. 55 (10) , 906-919
The role and clinical implications of microRNAs in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is common and one of the most aggressive of all human cancers. Recent studies have indicated that miRNAs, a class of small noncoding RNAs that regulate gene expression post-transcriptionally, directly contribute to HCC by targeting many critical regulatory genes. Several miRNAs are involved in hepatitis B or hepatitis C virus replication and virus-induced changes, whereas others participate in multiple intracellular signaling pathways that modulate apoptosis, cell cycle checkpoints, and growth-factor-stimulated responses. When disturbed, these pathways appear to result in malignant transformation and ultimately HCC development. Recently, miRNAs circulating in the blood have acted as possible early diagnostic markers for HCC. These miRNA also could serve as indicators with respect to drug efficacy and be prognostic in HCC patients. Such biomarkers would assist stratification of HCC patients and help direct personalized therapy. Here, we summarize recent advances regarding the role of miRNAs in HCC development and progression. Our expectation is that these and ongoing studies will contribute to the understanding of the multiple roles of these small noncoding RNAs in liver tumorigenesis.
- 31 October 2012
- Published by Springer Nature in Science China Life Sciences
- Vol. 55 (10) , 906-919
Open AccessThe role and clinical implications of microRNAs in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is common and one of the most aggressive of all human cancers. Recent studies have indicated that miRNAs, a class of small noncoding RNAs that regulate gene expression post-transcriptionally, directly contribute to HCC by targeting many critical regulatory genes. Several miRNAs are involved in hepatitis B or hepatitis C virus replication and virus-induced changes, whereas others participate in multiple intracellular signaling pathways that modulate apoptosis, cell cycle checkpoints, and growth-factor-stimulated responses. When disturbed, these pathways appear to result in malignant transformation and ultimately HCC development. Recently, miRNAs circulating in the blood have acted as possible early diagnostic markers for HCC. These miRNA also could serve as indicators with respect to drug efficacy and be prognostic in HCC patients. Such biomarkers would assist stratification of HCC patients and help direct personalized therapy. Here, we summarize recent advances regarding the role of miRNAs in HCC development and progression. Our expectation is that these and ongoing studies will contribute to the understanding of the multiple roles of these small noncoding RNAs in liver tumorigenesis.
- 22 September 2011
- Published by Wiley in Journal of Surgical Oncology
- Vol. 105 (7) , 687-691
Primary liver cancer presenting as pyogenic liver abscess: Characteristics, diagnosis, and management
Background and Objectives: Primary liver cancer (PLC) presenting as pyogenic liver abscess (PLA) is potentially life‐threatening, but has been occasionally reported, especially for cholangiocarcinoma.Methods: Medical records of nine patients who presented as PLA, but were eventually confirmed as hepatocellular carcinoma (HCC; n = 5) or intrahepatic cholangiocarcinoma (IHCC; n = 4), from September 1997 through April 2011, were retrospectively reviewed.Results: Presenting symptoms included fever, chills, right‐upper‐quadrant abdominal pain, nausea, vomiting, weight loss, and diarrhea. Physical signs included tenderness in the right‐upper‐quadrant abdomen, jaundice, and ascites. With the exception of elevated alpha‐fetoprotein (AFP) in HCC patients and elevated carbohydrate antigen 19‐9 (CA19‐9) in IHCC patients, lab results were not significantly different between these nine patients and PLA patients. All the nine patients underwent invasive treatment in addition to antibiotics.Conclusions: Elevated AFP and CA19‐9 could suggest HCC and IHCC in patients with symptoms/signs typical of PLA. Contrast‐enhanced computed tomography could be helpful in patients with normal AFP and CA19‐9. Making an accurate and early diagnosis and seizing the opportunity of surgery are essential to improve the management strategies of patients with PLC mimicking PLA. J. Surg. Oncol. 2012; 105:687–691.
- 22 September 2011
- Published by Wiley in Journal of Surgical Oncology
- Vol. 105 (7) , 687-691
Primary liver cancer presenting as pyogenic liver abscess: Characteristics, diagnosis, and management
Background and Objectives: Primary liver cancer (PLC) presenting as pyogenic liver abscess (PLA) is potentially life‐threatening, but has been occasionally reported, especially for cholangiocarcinoma.Methods: Medical records of nine patients who presented as PLA, but were eventually confirmed as hepatocellular carcinoma (HCC; n = 5) or intrahepatic cholangiocarcinoma (IHCC; n = 4), from September 1997 through April 2011, were retrospectively reviewed.Results: Presenting symptoms included fever, chills, right‐upper‐quadrant abdominal pain, nausea, vomiting, weight loss, and diarrhea. Physical signs included tenderness in the right‐upper‐quadrant abdomen, jaundice, and ascites. With the exception of elevated alpha‐fetoprotein (AFP) in HCC patients and elevated carbohydrate antigen 19‐9 (CA19‐9) in IHCC patients, lab results were not significantly different between these nine patients and PLA patients. All the nine patients underwent invasive treatment in addition to antibiotics.Conclusions: Elevated AFP and CA19‐9 could suggest HCC and IHCC in patients with symptoms/signs typical of PLA. Contrast‐enhanced computed tomography could be helpful in patients with normal AFP and CA19‐9. Making an accurate and early diagnosis and seizing the opportunity of surgery are essential to improve the management strategies of patients with PLC mimicking PLA. J. Surg. Oncol. 2012; 105:687–691.
- 14 December 2010
- Vol. 90 (46) , 3251-4
[A survival analysis of patients with early-stage hepatocellular carcinoma fulfilling Milan criteria and undergoing hepatectomy].
To summarize the experience of hepatectomy in patients with hepatocellular carcinoma fulfilling the Milan criteria and analyze the clinicopathological factors for patient survival and tumor recurrence. The clinicopathological data of 104 patients with early-stage hepatocellular carcinoma fulfilling the Milan criteria and underwent hepatectomy at Peking Union Medical College Hospital between April 2003 and June 2009 were retrospectively analyzed. The median follow-up was 24 months. There were 54 recurrent cases. The 1-, 3- and 5-year cumulative disease-free survival rate were 63.0%, 32.6% and 22.4% respectively. Neither univariate analysis nor multivariate analysis indicated any factor significantly correlated with recurrence (P>0.05). The cumulative overall survival rate at 1, 3 and 5 years were 88.8%, 68.1% and 68.1% respectively. Univariate analysis revealed that blood transfusion (P=0.000), involvement of hepatic capsule (P=0.000) and postoperative transarterial chemotherapy (P=0.049) were significantly correlated with survival. And multivariate analysis indicated that blood transfusion (P=0.001) and involvement of hepatic capsule (P=0.000) were independent prognostic factors for survival. For the patients with early-stage hepatocellular carcinoma and compensated liver function fulfilling the Milan criteria, hepatectomy serves as the preferred treatment strategy.
- 14 December 2010
- Vol. 90 (46) , 3251-4
[A survival analysis of patients with early-stage hepatocellular carcinoma fulfilling Milan criteria and undergoing hepatectomy].
To summarize the experience of hepatectomy in patients with hepatocellular carcinoma fulfilling the Milan criteria and analyze the clinicopathological factors for patient survival and tumor recurrence. The clinicopathological data of 104 patients with early-stage hepatocellular carcinoma fulfilling the Milan criteria and underwent hepatectomy at Peking Union Medical College Hospital between April 2003 and June 2009 were retrospectively analyzed. The median follow-up was 24 months. There were 54 recurrent cases. The 1-, 3- and 5-year cumulative disease-free survival rate were 63.0%, 32.6% and 22.4% respectively. Neither univariate analysis nor multivariate analysis indicated any factor significantly correlated with recurrence (P>0.05). The cumulative overall survival rate at 1, 3 and 5 years were 88.8%, 68.1% and 68.1% respectively. Univariate analysis revealed that blood transfusion (P=0.000), involvement of hepatic capsule (P=0.000) and postoperative transarterial chemotherapy (P=0.049) were significantly correlated with survival. And multivariate analysis indicated that blood transfusion (P=0.001) and involvement of hepatic capsule (P=0.000) were independent prognostic factors for survival. For the patients with early-stage hepatocellular carcinoma and compensated liver function fulfilling the Milan criteria, hepatectomy serves as the preferred treatment strategy.